Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Acuta Capital Partners LLC

Acuta Capital Partners LLC lowered its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 66.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,000 shares of the company's stock after selling 90,400 shares during the period. Vaxcyte comprises 3.7% of Acuta Capital Partners LLC's holdings, making the stock its 10th biggest holding. Acuta Capital Partners LLC's holdings in Vaxcyte were worth $3,684,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Wells Fargo & Company MN increased its holdings in shares of Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after buying an additional 25,257 shares in the last quarter. Diversified Trust Co acquired a new stake in shares of Vaxcyte during the fourth quarter worth $1,433,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vaxcyte by 23.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after purchasing an additional 4,962 shares during the last quarter. TimesSquare Capital Management LLC increased its stake in Vaxcyte by 53.7% in the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after purchasing an additional 144,516 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Vaxcyte by 186.2% during the 3rd quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock worth $6,022,000 after buying an additional 34,287 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PCVX has been the topic of several research analyst reports. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Guggenheim restated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Cantor Fitzgerald started coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $136.50.

Insider Buying and Selling at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the transaction, the chief operating officer now directly owns 205,695 shares of the company's stock, valued at approximately $17,735,022.90. This trade represents a 3.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 24,000 shares of company stock worth $1,946,720. Insiders own 3.10% of the company's stock.

Vaxcyte Price Performance

Shares of PCVX opened at $35.24 on Friday. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06. The stock has a 50 day simple moving average of $51.80 and a two-hundred day simple moving average of $78.18. The firm has a market cap of $4.54 billion, a P/E ratio of -7.66 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.